Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has initiated an immediate review of clinical trials involving the international transfer of Americans’ living cells for genetic engineering and subsequent …
FDA Investigates Clinical Trials Sending U.S. DNA Overseas Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has unveiled the Commissioner’s National Priority Voucher (CNPV) program, aiming to streamline the drug approval process and address critical health …
FDA Introduces Priority Voucher Program to Accelerate Drug Approvals Read More
WASHINGTON, D.C. — The Centers for Disease Control and Prevention (CDC) has issued a food safety alert following a multistate outbreak of Salmonella infections linked to pistachio cream. Four individuals in …
CDC Warns of Salmonella Outbreak Linked to Pistachio Cream Read More
WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has announced a three-month extension for its review of the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), submitted …
FDA Extends Review Period for Ruxolitinib Cream for Pediatric Atopic Dermatitis Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory …
FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma Read More
KING OF PRUSSIA, PA — The U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® (garadacimab-gxii), developed by CSL, as the first treatment targeting factor XIIa for the prevention of …
FDA Approves ANDEMBRY® for Preventing Hereditary Angioedema Attacks Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced the official launch of Elsa, a cutting-edge generative Artificial Intelligence (AI) tool designed to optimize efficiency across the …
Revolutionizing FDA Operations: Meet Elsa, the AI Tool Transforming Public Health Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced receiving a Refuse-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) of MOLBREEVI, …
FDA Requests Additional Data for Savara’s MOLBREEVI Application Read More